ALX Oncology Files 8-K: Director Changes & Financials
Ticker: ALXO · Form: 8-K · Filed: Oct 4, 2024 · CIK: 1810182
Sentiment: neutral
Topics: corporate-governance, officer-changes, financial-statements
Related Tickers: ALXO
TL;DR
ALX Oncology's 8-K shows director changes and financial updates as of Sept 30, 2024.
AI Summary
ALX Oncology Holdings Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes financial statements and exhibits, with the report dated October 4, 2024.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with the filing of financial statements, can signal significant internal developments that may affect the company's future performance.
Key Numbers
- 001-39386 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-0642577 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- October 4, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific changes were made regarding directors and officers?
The filing reports on the departure of directors, election of directors, and appointment of certain officers.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated September 30, 2024.
When was this 8-K form filed with the SEC?
This 8-K form was filed on October 4, 2024.
What are the principal executive offices of ALX Oncology Holdings Inc.?
The principal executive offices are located at 323 Allerton Avenue, South San Francisco, California 94080.
What other items are covered in this 8-K filing besides director and officer changes?
The filing also covers compensatory arrangements of certain officers and includes financial statements and exhibits.
Filing Stats: 1,000 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2024-10-04 09:00:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
- $503,880 — single, lump sum, cash payment equal to $503,880, and for Company-paid premiums for COBR
Filing Documents
- alxo-20240930.htm (8-K) — 50KB
- 0000950170-24-112734.txt ( ) — 161KB
- alxo-20240930.xsd (EX-101.SCH) — 25KB
- alxo-20240930_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (formatted as Inline XBRL) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALX ONCOLOGY HOLDINGS INC. Date: October 4, 2024 By: /s/ Peter Garcia Peter Garcia Chief Financial Officer 2